Agilent introduces SureSelect Clinical Research Exome V2

Agilent Technologies has announced the launch of an enhanced target enrichment solution for next-generation DNA sequencing.

It is able to deliver more than 1,000 additional disease-relevant targets compared to the earlier version of the product, and represents the only exome on the market offering a curated, annotated list of included genes, as well as evidence for disease relevance.

Additionally, it provides in excess of 75,000 splice sites of noncoding exons, over 12,000 previously-reported deep intronic variants, and more than 800 variants in promoter regions, assisting the discovery and identification of new disease-associated targets.

Targets incorporated into the system were identified through a curation effort led by Emory University and the Children's Hospital of Philadelphia, both of which also contributed to the development of the first version of the product.

Herman Verrelst, Agilent's vice-president and general manager of its genomics solutions and clinical applications division, said: "Since Agilent released the first commercial exome in 2009, we have been consistently innovating to deliver one of the best-in-class products that enable accurate identification of novel and disease-relevant genetic variants in constitutional samples."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.